{
  "nct_id": "NCT06914999",
  "official_title": "Assessment of Radiation-Induced Vascular Complications in Patients With Head and Neck Cancers With PET/CT Imaging",
  "brief_title": "Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer",
  "cancer_type_display": "A study for patients with various stages of head and neck cancers, including oropharyngeal, hypopharyngeal, and laryngeal squamous cell carcinoma.",
  "cancer_tags": [
    "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
    "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
    "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
    "Head and Neck Squamous Cell Carcinoma",
    "Hypopharyngeal Squamous Cell Carcinoma",
    "Laryngeal Squamous Cell Carcinoma",
    "Oropharyngeal Squamous Cell Carcinoma",
    "Stage III Hypopharyngeal Carcinoma AJCC v8",
    "Stage III Laryngeal Cancer AJCC v8",
    "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
    "Stage IVA Hypopharyngeal Carcinoma AJCC v8",
    "Stage IVA Laryngeal Cancer AJCC v8",
    "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
    "Stage IVB Hypopharyngeal Carcinoma AJCC v8",
    "Stage IVB Laryngeal Cancer AJCC v8",
    "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
  ],
  "link_to_trial": "https://clinicaltrials.gov/study/NCT06914999",
  "phase": "Early Phase 1",
  "recruitment_status": "RECRUITING",
  "last_update_date": "2025-10-22",
  "enrollment": 20,
  "min_age": 18,
  "max_age": null,
  "sex": "ALL",
  "is_metastatic_allowed": null,
  "performance_status_scale": null,
  "performance_status_values": null,
  "min_prior_lines": null,
  "max_prior_lines": null,
  "prior_treatments_required": null,
  "prior_treatments_excluded": [
    "Chemotherapy or radiotherapy within 4 weeks prior to entering the study",
    "Receiving any other investigational agents within 21 days",
    "Planned to receive any immunotherapy agent during radiotherapy"
  ],
  "principal_investigator": "Amol M Takalkar, MD, MS, MBA, FACNM",
  "site_name": "Emory University Hospital Midtown",
  "contact_email": "nashwa.jarkas@emory.edu",
  "contact_phone": "404-727-2193",
  "locations": [
    {
      "facility": "Emory University Hospital Midtown",
      "status": "RECRUITING",
      "city": "Atlanta",
      "state": "Georgia",
      "zip": "30308",
      "country": "United States",
      "contacts": [
        {
          "name": "Nashwa M. Jarkas",
          "role": "CONTACT",
          "phone": "404-727-2193",
          "email": "nashwa.jarkas@emory.edu"
        },
        {
          "name": "Amol M. Takalkar, MD, MS, MBA, FACNM",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "geoPoint": {
        "lat": 33.749,
        "lon": -84.38798
      }
    }
  ],
  "key_inclusion_summary": [
    "Must be 18 years of age or older.",
    "Diagnosis of specific stages of squamous cell carcinoma of the oropharynx (HPV-negative or HPV-associated), larynx, or hypopharynx.",
    "Planned to receive curative-intent, organ preservation (non-surgical) treatment with concurrent chemoradiotherapy.",
    "Females of childbearing potential must have a negative pregnancy test and agree to use effective contraception."
  ],
  "key_exclusion_summary": [
    "Previous chemotherapy or radiotherapy within 4 weeks prior to study entry.",
    "Currently receiving or planning to receive other investigational agents or immunotherapy.",
    "History of significant cardiovascular disease within 3 months prior to study entry.",
    "Uncontrolled intercurrent illness, such as ongoing infection, symptomatic congestive heart failure, or unstable angina.",
    "Pregnant women, prisoners, or adults unable to consent."
  ]
}